This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01647451?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
